Who are Accent Therapeutics's investors?

Accent Therapeutics's investors include Atlas Venture, Droia Ventures, EcoR1 Capital, GV (Google Ventures), The Column Group, JJDC, Johnson & Johnson Innovation – JJDC, Mirae Asset Venture Investment.

How much funding has Accent Therapeutics raised?

Accent Therapeutics has disclosed $75M raised across 1 round.

Accent Therapeutics

Founded 2017 · 31 employees on LinkedIn · 14 known investors

Find your way into Accent Therapeutics

Your email: who you already know at Accent Therapeutics, and who your contacts know
2nd- and 3rd-degree connections: people you know who worked, studied or invested with the Accent Therapeutics team
Your LinkedIn: the connections who can make the intro for you

We rank every route by how warm it is, so you raise on warm intros instead of cold emails.

Accent Therapeutics is a biotechnology company focused on discovering and developing small molecule drugs to improve health outcomes for cancer patients. It operates in oncology-focused drug discovery and development.

Biotech Healthtech Longevity

Investors · 14

Atlas Venturelisted by Atlas VentureCambridge · $500K – $1M

How we know: Atlas Venture's portfolio page · a partner's Signal profile · prnewswire.com · the VCSheet dataset · Not right? Tell us

Droia Ventureslisted by Droia VenturesLuxembourg · $540K

How we know: Droia Ventures's portfolio page · prnewswire.com · the VCSheet dataset · Not right? Tell us

EcoR1 Capitallisted by EcoR1 CapitalSan Francisco

How we know: prnewswire.com · Not right? Tell us

GV (Google Ventures)listed by GV (Google Ventures)Mountain View · $250K – $50M

How we know: GV (Google Ventures)'s portfolio page · prnewswire.com · Not right? Tell us

The Column Grouplisted by The Column GroupSan Francisco · $30M

How we know: The Column Group's portfolio page · a partner's Signal profile · prnewswire.com · the VCSheet dataset · Not right? Tell us

JJDCreportedNew Brunswick · $500K – $5M

How we know: fiercebiotech.com · Not right? Tell us

Johnson & Johnson Innovation – JJDCreportedNew Brunswick

How we know: prnewswire.com · Not right? Tell us

Mirae Asset Venture Investmentreported$594K – $54M

How we know: prnewswire.com · Not right? Tell us

Also in the syndicate · 6

AbbVie VenturesBristol Myers SquibbMirae Asset CapitalMirae Asset Capital Life ScienceleadThe Mark Foundation for Cancer ResearchTimefolio Capital

Funding

SEC filings, press & company announcements

$75M disclosed across 1 round · 2024

$75MSeries CJan 2024 · 3 sources
Mirae Asset Capital Life Science (lead), AbbVie Ventures, Atlas Venture, Bristol Myers Squibb, Droia Ventures, EcoR1 Capital, GV, JJDC, Johnson & Johnson Innovation – JJDC, Inc., Mirae Asset Capital, Mirae Asset Venture Investment, The Column Group, The Mark Foundation for Cancer Research, Timefolio Capital
Source ↗

Source: company announcements and press reports — follow each round's link for the claim.

In the news

Accent Therapeutics Announces $75 Million Series C Financing to Advance Small Molecule Precision Cancer Therapiesprnewswire.com · Jan 2024

Accent Therapeutics Raises $75M in Series C Fundingfinsmes.com · Jan 2024

Frequently asked questions

What does Accent Therapeutics do?: Accent Therapeutics is a biotechnology company focused on discovering and developing small molecule drugs to improve health outcomes for cancer patients. It operates in oncology-focused drug discovery and development.
Who are Accent Therapeutics's investors?: Accent Therapeutics's investors include Atlas Venture, Droia Ventures, EcoR1 Capital, GV (Google Ventures), The Column Group, JJDC, Johnson & Johnson Innovation – JJDC, Mirae Asset Venture Investment.
How much funding has Accent Therapeutics raised?: Accent Therapeutics has disclosed $75M raised across 1 round.